This strategy is unorthodox, but then Lipitor has been no ordinary pill.
For Ireland, which produces some of the world's biggest-selling branded drugs, the patent cliff could be an economic sinkhole.
But there's a larger question here, too.
Pfizer wants to expand Prevnar's reach beyond childhood.
Has Amgen proven itself a card-carrying member of Big Pharma?
If Pfizer lets Lipitor go, what's left?
How is AstraZeneca really doing?
Is Abbott sounding too optimistic?
It isn't often that the two biggest of Big Pharma find themselves in a patent fight.
Can J&J figure this out?
There's both good news and bad news.
A return of a Tylenol product may be the beginning of the end of the bad news.
Amgen is getting lots of good news.
President Obama's deficit-cutting plan hits pharma with a one-two-three punch.
One in eight jobs will be lost.
Novartis has two things to say.
Lipitor goes off patent later this year.
The "Dendreon Effect" reaches far and wide.
Big drugmakers are one step ahead of the cash-hoarders. They've already been squirreling their money away.
You can't blame Pfizer for trying to squeeze every last bit of sales from Lipitor.